Literature DB >> 1494861

The effect of protein binding on ivermectin uptake by bovine brain microvessel endothelial cells.

K L Audus1, S R Knaub, F L Guillot, J M Schaeffer.   

Abstract

The effect of albumin binding on ivermectin uptake and transfer across the endothelial component of the blood-brain barrier (BBB) was determined with an in vitro model comprised of bovine brain microvessel endothelial cell (BMEC) monolayers. Cellular uptake of ivermectin was limited in the absence of albumin and 90% inhibited in the presence of 10% albumin. Cell membrane association of ivermectin, as followed by fluorescent probe labelling, was observed only at high (micromolar) concentrations of the drug. Membrane association was about 75% inhibited in the presence of albumin. Similarly, transfer across BMEC monolayers was restricted, equivalent to that of BBB impermeant markers. Unlike the uptake studies, however, albumin had little effect on the transfer of ivermectin across BMEC monolayers. These results support recent in vivo findings on the distribution of ivermectin into the brain and suggest that ivermectin has only a limited affinity for the endothelial component of the normal BBB.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1494861     DOI: 10.1007/bf01839186

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  29 in total

1.  Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporin A.

Authors:  D J Begley; L K Squires; B V Zloković; D M Mitrović; C C Hughes; P A Revest; J Greenwood
Journal:  J Neurochem       Date:  1990-10       Impact factor: 5.372

2.  Anticonvulsant effects of ivermectin in genetically-epileptic chickens.

Authors:  E C Crichlow; P R Mishra; R D Crawford
Journal:  Neuropharmacology       Date:  1986-10       Impact factor: 5.250

3.  Response to physostigmine administration in collie dogs exhibiting ivermectin toxicosis.

Authors:  W J Tranquilli; A J Paul; R L Seward; K S Todd; J A Dipietro
Journal:  J Vet Pharmacol Ther       Date:  1987-03       Impact factor: 1.786

4.  Pharmacokinetic studies of ivermectin: effects of formulation.

Authors:  P K Lo; D W Fink; J B Williams; J Blodinger
Journal:  Vet Res Commun       Date:  1985-09       Impact factor: 2.459

5.  Angiotensin peptide regulation of fluid-phase endocytosis in brain microvessel endothelial cell monolayers.

Authors:  F L Guillot; K L Audus
Journal:  J Cereb Blood Flow Metab       Date:  1990-11       Impact factor: 6.200

6.  Plasma membrane fluidity measurements on whole living cells by fluorescence anisotropy of trimethylammoniumdiphenylhexatriene.

Authors:  J G Kuhry; G Duportail; C Bronner; G Laustriat
Journal:  Biochim Biophys Acta       Date:  1985-04-22

7.  Ivermectin toxicosis in a dog.

Authors:  D M Houston; J Parent; K J Matushek
Journal:  J Am Vet Med Assoc       Date:  1987-07-01       Impact factor: 1.936

8.  Characteristics of the large neutral amino acid transport system of bovine brain microvessel endothelial cell monolayers.

Authors:  K L Audus; R T Borchardt
Journal:  J Neurochem       Date:  1986-08       Impact factor: 5.372

9.  1-[4-(Trimethylamino)phenyl]-6-phenylhexa-1,3,5-triene: synthesis, fluorescence properties, and use as a fluorescence probe of lipid bilayers.

Authors:  F G Prendergast; R P Haugland; P J Callahan
Journal:  Biochemistry       Date:  1981-12-22       Impact factor: 3.162

10.  The application of bovine brain microvessel endothelial-cell monolayers grown onto polycarbonate membranes in vitro to estimate the potential permeability of solutes through the blood-brain barrier.

Authors:  M V Shah; K L Audus; R T Borchardt
Journal:  Pharm Res       Date:  1989-07       Impact factor: 4.200

View more
  8 in total

1.  Evaluation of the role of P-glycoprotein in ivermectin uptake by primary cultures of bovine brain microvessel endothelial cells.

Authors:  J M Rose; S L Peckham; J L Scism; K L Audus
Journal:  Neurochem Res       Date:  1998-02       Impact factor: 3.996

2.  Potential therapeutic effects of Ivermectin in COVID-19.

Authors:  Nastaran Barati; Seyedmousa Motavallihaghi; Banafsheh Nikfar; Shahla Chaichian; Amir Abbas Momtazi-Borojeni
Journal:  Exp Biol Med (Maywood)       Date:  2022-06-10

3.  Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants.

Authors:  Océane Delandre; Mathieu Gendrot; Priscilla Jardot; Marion Le Bideau; Manon Boxberger; Céline Boschi; Isabelle Fonta; Joel Mosnier; Sébastien Hutter; Anthony Levasseur; Bernard La Scola; Bruno Pradines
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-02

4.  Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review.

Authors:  Subhrojyoti Bhowmick; Amit Dang; B N Vallish; Sumit Dang
Journal:  Drug Saf       Date:  2021-04-16       Impact factor: 5.606

Review 5.  COVID-19: potential therapeutics for pediatric patients.

Authors:  Nour K Younis; Rana O Zareef; Ghina Fakhri; Fadi Bitar; Ali H Eid; Mariam Arabi
Journal:  Pharmacol Rep       Date:  2021-08-30       Impact factor: 3.024

Review 6.  A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at Its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody.

Authors:  David E Scheim
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

7.  Ivermectin as a multifaceted drug in COVID-19: Current insights.

Authors:  Ankur Khandelwal; Gyaninder Pal Singh; Shaista Jamil
Journal:  Med J Armed Forces India       Date:  2021-07-26

8.  Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19.

Authors:  Ricardo Peña-Silva; Stephen B Duffull; Andrew C Steer; Sandra X Jaramillo-Rincon; Amanda Gwee; Xiao Zhu
Journal:  Br J Clin Pharmacol       Date:  2020-07-17       Impact factor: 3.716

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.